{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T03:08:33Z","timestamp":1780110513989,"version":"3.54.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jaut.2022.102893","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T07:07:25Z","timestamp":1661324845000},"page":"102893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Comparative effectiveness of preventive treatment with dimethyl fumarate-loaded solid lipid nanoparticles and oral dimethyl fumarate in a mouse model of multiple sclerosis"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0791-6447","authenticated-orcid":false,"given":"Gisela","family":"Bevilacqua Rolfsen Ferreira da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Pereira das Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana Cristina","family":"Roque Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anselmo","family":"Gomes de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1bio","family":"de Lima Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Jos\u00e9","family":"Cerqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2022.102893_bib1","doi-asserted-by":"crossref","first-page":"11783","DOI":"10.3390\/ijms130911783","article-title":"Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters","volume":"13","author":"Lee","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jaut.2022.102893_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/path.2582","article-title":"Enhanced number and activity of mitochondria in multiple sclerosis lesions","volume":"219","author":"Witte","year":"2009","journal-title":"J. Pathol."},{"key":"10.1016\/j.jaut.2022.102893_bib3","first-page":"389","article-title":"Pharmaceutical approval update","volume":"38","author":"Goldenberg","year":"2013","journal-title":"P T"},{"key":"10.1016\/j.jaut.2022.102893_bib4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","article-title":"Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway","volume":"134","author":"Linker","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.jaut.2022.102893_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.msard.2017.09.014","article-title":"Delayed lymphocyte re-population following discontinuation of dimethyl fumarate and after switching to other disease modifying drug therapies","volume":"18","author":"Khatri","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jaut.2022.102893_bib6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40120-019-0127-2","article-title":"Real-world characterization of dimethyl fumarate-related gastrointestinal events in multiple sclerosis: management strategies to improve persistence on treatment and patient outcomes","volume":"8","author":"Min","year":"2019","journal-title":"Neurol Ther"},{"key":"10.1016\/j.jaut.2022.102893_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1055\/s-0033-1343796","article-title":"BG-12 in multiple sclerosis","volume":"33","author":"Phillips","year":"2013","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.jaut.2022.102893_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/bdd.364","article-title":"Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters","volume":"24","author":"Werdenberg","year":"2003","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.jaut.2022.102893_bib9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2125.2004.02145.x","article-title":"Pharmacokinetics of oral fumarates in healthy subjects","volume":"58","author":"Litjens","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jaut.2022.102893_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2006.03094.x","article-title":"Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration","volume":"145","author":"Schilling","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2022.102893_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577163","article-title":"Enhanced cognitive performance in experimental autoimmune encephalomyelitis mice treated with dimethyl fumarate after the appearance of disease symptoms","volume":"340","author":"das Neves","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jaut.2022.102893_bib12","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/nprot.2006.285","article-title":"Active induction of experimental allergic encephalomyelitis","volume":"1","author":"Stromnes","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jaut.2022.102893_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fncel.2012.00033","article-title":"Lipocalin 2 is present in the EAE brain and is modulated by natalizumab","volume":"6","author":"Marques","year":"2012","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.jaut.2022.102893_bib14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.biopha.2017.09.110","article-title":"Anti-encephalitogenic effects of ethyl pyruvate are reflected in the central nervous system and the gut","volume":"96","author":"Djedovic","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jaut.2022.102893_bib15","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.4049\/jimmunol.1402302","article-title":"A comparative analysis of multiple sclerosis-relevant anti-inflammatory properties of ethyl pyruvate and dimethyl fumarate","volume":"194","author":"Miljkovic","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2022.102893_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaut.2017.09.009","article-title":"Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis","volume":"86","author":"Diebold","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2022.102893_bib17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","article-title":"Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations","volume":"6","author":"Fox","year":"2016","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.jaut.2022.102893_bib18","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2022.102893_bib19","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1523-1747.2003.12605.x","article-title":"Dimethylfumarate is a potent inducer of apoptosis in human T cells","volume":"121","author":"Treumer","year":"2003","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jaut.2022.102893_bib20","first-page":"P1037","volume":"vol. 278239","author":"Longbrake","year":"2019"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841122001019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841122001019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:30:28Z","timestamp":1760257828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841122001019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":20,"alternative-id":["S0896841122001019"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2022.102893","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of preventive treatment with dimethyl fumarate-loaded solid lipid nanoparticles and oral dimethyl fumarate in a mouse model of multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2022.102893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102893"}}